March 21st 2023
At a prespecified analysis of the CARTITUDE-1 trial with a median follow-up of approximately 28 months, treatment with cilta-cel continued to elicit positive responses and maintained a favorable risk/benefit profile for patients with multiple myeloma.
February 22nd 2023
QOL in Patients Receiving Axi-Cel Align With Clinical Trial FindingsDecember 12th 2022
In the real-world setting. Patients treated with the chimeric antigen receptor T-cell agent, axicabtagene ciloleucel experience similar quality-of-life outcomes to patients who were treated in clinical trials.
FDA Clears IND for BEAM-201 in Relapsed/Refractory T-ALL/T-LLDecember 5th 2022
The clinical hold for the development of BEAM-201 has been lifted, allowing investigators to assess the agent in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/ T-cell lymphoblastic lymphoma.
FDA Grants RMAT and Fast Track Designations to Allogeneic CAR T-Cell Therapy for B-NHLNovember 30th 2022
The allogeneic CAR T-cell therapy CB-010 received regenerative medicine advanced therapy and Fast Track designations for the treatment of patients with B-cell non-Hodgkin lymphoma.
UCART19 Shows Promising Safety/Efficacy in Adult Patients With B-Cell ALLNovember 30th 2022
Findings from the phase 1 CALM study evaluating the allogeneic genome-edited anti-CD19 chimeric antigen receptor T-cell product UCART19 show it can be safely used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
CD19-/CD22-CAR T Cells Elicits Durable Remissions in Children With R/R B-Cell ALLNovember 22nd 2022
In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.
Treatment Possibilities for R/R Multiple Myeloma After BCMA-Directed CAR T-Cell TherapyNovember 7th 2022
Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.
Allogeneic CAR T-Cell Therapy May Provide Alternate Options in ALLOctober 24th 2022
In an interview with Targeted Oncology, Nitin Jain, MD, further discussed the ongoing research of allogeneic chimeric antigen receptor T cells as treatment for patients with ALL. He also notes what future research must examine to further the field.
Trial of CAR T-Cell Therapy Targeting GPRC5D Shows Efficacy in Resistant Multiple MyelomaOctober 5th 2022
The first trial investigating a chimeric antigen receptor therapy to target GPRC5D in patients with resistant multiple myeloma reveals remissions in 70.6% of the enrolled patients.
Integrating CAR T-Cell Therapy Into Community Oncology PracticesOctober 3rd 2022
In an interview with Targeted Oncology, Peter A. McSweeney discussed the ways in which community oncology centers are implementing chimeric antigen receptor T-cell therapy into their practice and the challenges that come with it.
In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?September 29th 2022
With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.
T-Cell Redirection Therapy Shows Promise As Salvage Therapy in R/R Multiple MyelomaSeptember 15th 2022
In a retrospective analysis of 115 patients with relapsed/refractory multiple myeloma who progressed after therapy on a bispecific antibody, researchers found that the myeloma patients can be salvaged with sequential T-cell redirection therapy.
CLDN6 CAR T-Cell Therapy Elicits Clinical Activity in Relapsed/Refractory Advanced Solid TumorsSeptember 9th 2022
The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Roundtable Discussion: Barriers to CAR T-Cell Therapy for DLBCL Lead to Debate About Targeted TherapyAugust 27th 2022
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.
Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL StudyAugust 19th 2022
Treatment with CD30 chimeric antigen receptor T-cell therapy combined with a monoclonal antibody has begun in the phase 1b ACTION study of patients with relapsed or refractory classical Hodgkin lymphoma.
CAR T-Cell Treatment at Higher Doses Reveal Beneficial Survival Data Without Worry of Added ToxicityAugust 12th 2022
Tisagenlecleucel boosted survival rates in children with B-cell lymphoblastic leukemia. Further research will be planned to examine the data and analyze additional clinical variables.
Second-Line Lisocabtagene Maraleucel Provides Benefit in Large B-Cell LymphomaAugust 10th 2022
Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.